KRAS and malignant colon neoplasm: Specifically, in three screening studies [39,51,86] that tested against melanoma (M-14 and SK-Mel-19), K-RAS-mutant lung cancer (A-549, H-23, and H-1573), and colon cancer (HCT116 and RKO) cell lines, several benzimidazoles showed inhibitory effects, but the levels of these effects differed depending on the benzimidazole type.